deoxyglucose has been researched along with Female Genital Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, R; Babar, S; Blagden, S; Carme, S; Chen, M; Curry, E; Dina, R; El-Bahrawy, MA; Gabra, H; Gungor, H; Krachey, E; Madison, S; Morris, SR; Pickford, E; Rama, N; Saleem, A; Salinas, C; Santiago-Walker, A; Smith, DA; Stronach, EA | 1 |
| Cailleux, N; Colombet-Lamau, C; de Beco, V; Grahek, D; Kerrou, K; Montravers, F; Petegnief, Y; Talbot, JN; Younsi, N | 1 |
1 review(s) available for deoxyglucose and Female Genital Neoplasms
| Article | Year |
|---|---|
[(18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers].
Topics: Breast Neoplasms; Deoxyglucose; Female; Fluorine Radioisotopes; Genital Neoplasms, Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tomography, Emission-Computed; Uterine Cervical Neoplasms | 2001 |
1 trial(s) available for deoxyglucose and Female Genital Neoplasms
| Article | Year |
|---|---|
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.
Topics: Antineoplastic Agents; Biomarkers; Biopsy; Blood Glucose; Deoxyglucose; Diamines; Drug Interactions; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Genital Neoplasms, Female; Humans; Oncogene Protein v-akt; Positron-Emission Tomography; Pyrazoles; Radiopharmaceuticals; Treatment Outcome | 2015 |